Oxygenta Pharmaceutical Ltd. Reports Widened Net Loss and Negative Net Worth

Net Loss: ₹17.57 crore
Net Worth: ₹(42.69) crore

Reader Takeaway: Wider losses and negative equity signal distress, though new parent company support offers a glimmer of hope.

What just happened

Oxygenta Pharmaceutical Ltd. reported a net loss of ₹17.57 crore for the financial year 2025-26, a significant increase from the ₹10.30 crore loss in the previous year. Revenue from operations saw a slight uptick to ₹112.98 crore from ₹109.30 crore. However, total expenses grew by 8.40% to ₹135.45 crore, outpacing revenue growth. The company's net worth has turned sharply negative, standing at ₹(42.69) crore.

Why this matters

The widening losses and negative net worth raise serious concerns about Oxygenta Pharmaceutical's financial stability. Independent auditors have issued a 'material uncertainty' warning regarding the company's ability to continue as a going concern. This indicates a significant risk for shareholders about the company's long-term viability.

The backstory

Virupaksha Organics Limited acquired a 56.5% stake in Oxygenta Pharmaceutical on June 20, 2025, becoming its promoter. The company is now a subsidiary of Virupaksha Organics. This ownership change comes at a time of considerable financial stress for Oxygenta.

What changes now

The new management, under Virupaksha Organics, is implementing a business restructuring plan. Proposed related party transactions for FY 2026-27 include sales of ₹130 crore and purchases of ₹120 crore with the holding company, along with loans and guarantees of ₹200 crore. Management aims for a return to positive EBITDA in FY 2026-27.

Risks to watch

Auditors have highlighted a material uncertainty about the company continuing as a going concern due to persistent losses and a negative net worth. Additionally, the company's manufacturing license was suspended for seven days by the Drugs Control Administration. A significant concentration risk exists, with approximately 63.87% of revenue coming from the holding company, Virupaksha Organics.

Peer comparison

Oxygenta Pharmaceutical operates in the pharmaceutical sector. While specific peer financial data for FY26 isn't provided in the filing, the company's negative net worth and auditor warnings place it in a vulnerable position compared to healthier industry players.

Context metrics (time-bound)

For FY 2025-26, Revenue from operations stood at ₹112.98 crore, while Total Expenses were ₹135.45 crore. Net loss was ₹17.57 crore. Net Worth was ₹(42.69) crore.

What to track next

Investors should monitor the progress of the business restructuring plan, the outcome of proposed related party transactions, and any further statements from auditors regarding the going concern status. Regulatory compliance and operational stability are also key factors.